Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity

NCT07304141 · Completed

Last updated 2026-05-28

This clinical trial examines how different medications may help reduce body mass index (BMI) in children who are overweight or obese.

Status Completed The study has finished.

Type Observational

Participants 128 people

Who can join Ages 10–18 · all sexes

Timeline Started 2023-12 · est. completion 2025-12

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT07304141 ↗

Description as written by the study sponsor.

The aim of the study is to examine the effects of pharmacological treatment for obesity on BMI trajectories and metabolic markers among patients in routine clinical care. A retrospective observational study. By collecting and analysing real-life data from the first children and adolescents in Sweden who have been offered pharmacological treatment for obesity, the results can contribute to a better understanding of how these treatments function in practice.

Treatments tested

Liraglutide 3 mg (Saxenda) Other

This is a retrospective observational study of adolescents aged 10-18 years with obesity who were offered liraglutide treatment at the Pediatric Clinic in Region Halland and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital, Sahlgrenska University Hospital.

Main thing measured	Change in Body Mass Index Standard Deviation Score (BMI SDS) over time
Sponsor	Göteborg University
Conditions studied	Obesity (Disorder), Child Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07304141 ↗